Oak Grove Capital LLC Reduces Position in Thermo Fisher Scientific Inc. $TMO

Oak Grove Capital LLC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 73.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,194 shares of the medical research company’s stock after selling 8,885 shares during the quarter. Oak Grove Capital LLC’s holdings in Thermo Fisher Scientific were worth $1,295,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in TMO. Revolve Wealth Partners LLC lifted its stake in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the period. Lafayette Investments Inc. lifted its stake in Thermo Fisher Scientific by 2.4% in the second quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock worth $376,000 after acquiring an additional 22 shares during the period. Root Financial Partners LLC lifted its stake in Thermo Fisher Scientific by 5.0% in the first quarter. Root Financial Partners LLC now owns 506 shares of the medical research company’s stock worth $252,000 after acquiring an additional 24 shares during the period. Rossmore Private Capital lifted its stake in Thermo Fisher Scientific by 0.5% in the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock worth $2,315,000 after acquiring an additional 24 shares during the period. Finally, FARMERS & MERCHANTS TRUST Co OF LONG BEACH lifted its stake in Thermo Fisher Scientific by 3.1% in the second quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock worth $326,000 after acquiring an additional 24 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,666 shares of company stock valued at $13,990,971 over the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on TMO shares. Evercore ISI raised their price target on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Cowen reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday. Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a report on Wednesday, October 8th. UBS Group increased their price objective on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, Wells Fargo & Company increased their price objective on Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a report on Thursday. Nineteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $595.75.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $573.07 on Monday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The business has a fifty day moving average price of $504.04 and a 200-day moving average price of $453.56. The company has a market capitalization of $216.40 billion, a PE ratio of 33.11, a PEG ratio of 3.35 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same period last year, the company earned $5.28 earnings per share. The company’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.